AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 4th, 2022 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 20, 2021, by and among Affinia Therapeutics Inc. (f/k/a TDTx Inc.), a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
EXCLUSIVE LICENSE AGREEMENT BETWEEN LONZA HOUSTON, INC. AND MASSACHUSETTS EYE AND EAR INFIRMARY AND THE SCHEPENS EYE RESEARCH INSTITUTE, INC. AND TDTX, INC. September 9, 2019Exclusive License Agreement • January 4th, 2022 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”), effective as of September 9, 2019 (“Effective Date”), is made between Lonza Houston, Inc., a Delaware corporation having a principal place of business at 14905 Kirby Drive, Houston, Texas 77047, United States, (“Lonza”) and Massachusetts Eye and Ear Infirmary, a not-for-profit Massachusetts corporation, having its principal place of business at 243 Charles Street, Boston, MA 02114, and The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having its principal place of business at 20 Staniford Street, Boston, MA 02114 (collectively “MEE”) (Lanza and MEE are collectively referred to herein as “Licensor(s)”), and TDTx Inc., a Delaware corporation having a principal place of business at One Broadway, 14th Floor, Kendall Square, Cambridge, MA 02142 (“TDTx” or “Licensee”). Lonza, MEE, and TDTx shall hereinafter collectively be referred to as the “Parties” and each, individually, as a “Party”.
STRATEGIC COLLABORATION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND AFFINIA THERAPEUTICS INC.Collaboration and License Agreement • January 4th, 2022 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances)
This Strategic Collaboration and License Agreement (this “Agreement”) is entered into as of April 14, 2020 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated, a corporation organized under the laws of The Commonwealth of Massachusetts (“Vertex”), and Affinia Therapeutics Inc., a corporation organized under the laws of Delaware with a place of business at 100 Beaver Street, Waltham, MA 02453 (“Company”). Vertex and Company each may be referred to herein individually as a “Party” or collectively as the “Parties.”
November 16th, 2021 Thomas Edward Leggett Newton Center, MA 02459 Dear Thomas:Protection Agreement • January 4th, 2022 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
Affinia Therapeutics Inc. (the “Company”) is pleased to offer you employment on the terms set forth in this letter agreement (the “Offer Letter”).
ContractAffinia Therapeutics Inc. • November 24th, 2021 • Biological products, (no disgnostic substances)
[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
EMPLOYMENT AGREEMENTEmployment Agreement • January 4th, 2022 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”), made as of August 27, 2019, is entered into between TDTx, Inc., a Delaware corporation (the “Company”), and Raken B. Modi (AKA Rick Modi) (the “Executive”).
SPONSORED RESEARCH COLLABORATION AGREEMENT BY AND BETWEEN THE INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL AND AFFINIA THERAPEUTICS INC.Research Collaboration Agreement • November 24th, 2021 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
This SPONSORED RESEARCH COLLABORATION AGREEMENT (this “Agreement” is made as of June 22, 2021 (the “Effective Date”), by and between Affinia Therapeutics Inc., having its principal offices at 43 Foundry Ave., Suite 120, Waltham, MA 02453 (“Affinia”) and The Institute of Molecular and Clinical Ophthalmology Basel with an address at Mittlere Strasse 91, CH-4031 Basel, Switzerland (“IOB”). Affinia and IOB are referred to individually as a “Party” and collectively as the “Parties”.
MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • November 24th, 2021 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances)
THIS MANUFACTURING SERVICES AGREEMENT (the “Agreement”) is made as of April 30th 2021 (the “Effective Date”) between LONZA HOUSTON, INC. located at 14905 Kirby Drive, Houston, TX 77047 (“LONZA”), and AFFINIA THERAPEUTICS, INC., a Delaware corporation with a place of business at 43 Foundry Ave., Suite 120, Waltham, MA 02453 (“CLIENT”), (each of LONZA and CLIENT, a “Party” and, collectively, the “Parties”).
ContractAffinia Therapeutics Inc. • November 24th, 2021 • Biological products, (no disgnostic substances)
[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
